What's most transformative about this drug approval is that this is the first time the FDA - the governmental arbiter of safe and effective medicine in the United States - has approved any substance derived from the cannabis plant.
Mice who received a combination of CBD and chemotherapy survived nearly three times as long as the mice given the placebo, and around twice as long as the mice given CBD or chemotherapy alone.
The American Osteopathic Association supports the reclassification of cannabis as a Schedule II Drug to facilitate advancement in clinical, public health, patient safety and health policy research, according to a resolution approved by the AOA House of Delegates.
Mounting evidence suggests that the inflammatory processes in the brain contribute to the pathologies of Parkinson's, Alzheimer's and HIV-Associated Neurocognitive Disorders.
The changes concern the reclassification of cannabis to make it a schedule 2 drug, allowing it to be prescribed by medical professionals and possessed lawfully by anybody with a valid medical prescription.
A unique cannabis strain that has the capacity to inhibit dendritic-dependent T-cells proliferation has been identified by researchers in Israel.
CBD delivered from Lexaria’s TurboCBDTM capsules was absorbed much more effectively than from the positive control, delivering 317% more CBD to blood at the 30-minute mark of the study.